1-6 of 6
Leigh Ellis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B006: Targeting EZH2 increases therapeutic efficacy of PD-1 blockade in models of prostate cancer

Anjali Sheahan, Katherine Morel, Deborah Burkhart, Sylvan Baca, David Labbè, Keven Roehle, Carla Calagua, Huihui Ye, Phillip Galbo, Sukanya Panja, Antonina Mitrofanova, Anis Hamid, Adam Kibel, Atish Choudhury, Mark Pomerantz, Matthew Freedman, Christopher Sweeney, Stephanie Dougan, Adam Sowalsky, Brian Olson, Massimo Loda, Leigh Ellis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B006.
https://doi.org/10.1158/1535-7163.TARG-19-B006
Published: 01 December 2019
View article titled, Abstract B006: Targeting EZH2 increases therapeutic efficacy of PD-1 blockade in models of prostate cancer
Journal Articles

Abstract B038: Dimethylaminoparthenolide-mediated inhibition of NF-κB decreases resistance to ADT by targeting AR variants in lethal prostate cancer

Katherine L Morel, Anis A Hamid, Leigh Ellis, Christopher J Sweeney
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B038.
https://doi.org/10.1158/1535-7163.TARG-19-B038
Published: 01 December 2019
View article titled, Abstract B038: Dimethylaminoparthenolide-mediated inhibition of NF-κB decreases resistance to ADT by targeting AR variants in lethal prostate cancer
Journal Articles

Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma

Leigh Ellis, Preeti Shah, Hans Hammers, Kristin Lehet, Paula Sotomayor, Gissou Azabdaftari, Mukund Seshadri, Roberto Pili
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 383–392.
https://doi.org/10.1158/1535-7163.MCT-11-0748
Published: 08 February 2012
View article titled, Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma
Open the PDF for Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma in another window
Journal Articles

Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study

Hans J. Hammers, Henk M. Verheul, Brenda Salumbides, Rajni Sharma, Michelle Rudek, Janneke Jaspers, Preeti Shah, Leigh Ellis, Li Shen, Silvia Paesante, Karl Dykema, Kyle Furge, Bin T. Teh, George Netto, Roberto Pili
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1525–1535.
https://doi.org/10.1158/1535-7163.MCT-09-1106
Published: 09 June 2010
View article titled, Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
Open the PDF for Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study in another window
Journal Articles

Epigenetics in cancer: Targeting chromatin modifications

Leigh Ellis, Peter W. Atadja, Ricky W. Johnstone
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (6): 1409–1420.
https://doi.org/10.1158/1535-7163.MCT-08-0860
Published: 10 June 2009
View article titled, Epigenetics in cancer: Targeting chromatin modifications
Open the PDF for Epigenetics in cancer: Targeting chromatin modifications in another window
Journal Articles

Characterization of the apoptotic and therapeutic activities of the histone deacetylase inhibitors LAQ824 and LBH589 using a mouse model of B cell lymphoma.

Leigh Ellis, Ralph Lindemann, Andrea Newbold, Kate Whitecross, Leonie Cluse, Marc Pelligrini, Andrew Wei, Clare Scott, Peter Atadja, Scott Lowe, Ricky Johnstone
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B132.
Published: 01 November 2007
View article titled, Characterization of the apoptotic and therapeutic activities of the histone deacetylase inhibitors LAQ824 and LBH589 using a mouse model of B cell lymphoma.